Oruka Therapeutics (ORKA) drew fresh investor attention after reporting encouraging interim Phase 1 data for ORKA-002, highlighting a long half-life and sustained IL-17 inhibition that could support less frequent dosing in psoriasis and hidradenitis suppurativa.

The positive ORKA-002 readout and recent conference presence appear to have kept interest high, with a 1-day share price return of 2.77% and year to date share price return of 18.15%. The 1-year total shareholder return of 172.65% points to strong momentum building around the story.

If this kind of early clinical traction has your attention, it could be a good moment to broaden your research and look at healthcare stocks as potential next candidates for your watchlist.

With the stock up 172.65% over the past year and the last close at $33.40 versus a consensus target of $55.67, investors now face a key question: is there still a buying opportunity here, or is future growth already priced in?

Price to Book of 3.3x: Is It Justified?

Oruka Therapeutics is trading on a P/B of 3.3x, which the data flags as good value against direct peers but more expensive than the broader US biotech group.

P/B compares the company’s market value to its net assets on the balance sheet. This can be a useful shorthand for early stage biotechs that do not yet generate revenue or profits. At this stage, investors are effectively paying for cash, intellectual property and the pipeline rather than current earnings.

Relative to a peer average P/B of 17.4x, ORKA’s 3.3x level looks materially lower. This suggests the market is pricing its assets at a discount compared to similar names. However, against the wider US Biotechs industry average of 2.6x, ORKA still carries a premium, implying investors are paying more per dollar of book value than for the sector overall.

Result: Price-to-book of 3.3x (ABOUT RIGHT)

However, you are still relying on early stage trial data, as well as on a company that currently records no revenue and a loss of $83.57m, both of which are key swing factors.

Build Your Own Oruka Therapeutics Narrative

If you see the story differently, or prefer to analyze the numbers yourself, you can build a custom view in minutes with Do it your way

A great starting point for your Oruka Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.

Ready for more investment ideas?

If Oruka is on your radar, do not stop there. Use the Simply Wall St Screener to widen your watchlist with focused, data driven ideas.

• Spot potential value in overlooked names by scanning these 863 undervalued stocks based on cash flows that current cash flows suggest may be priced below what they are worth.
• Explore developments in digital technologies by checking out these 24 AI penny stocks that are building and applying artificial intelligence across real world use cases.
• Monitor possible sector shifts by reviewing these 19 cryptocurrency and blockchain stocks tied to blockchain, digital assets and related infrastructure plays.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.